Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- EPS Acquires SMO in Taiwan
January 3, 2011
- Prospects for Simultaneous Global Development: 1 (1)
January 3, 2011
- Eisai, Elan Settle Zonegran Off-Label Promotion Disputes
January 3, 2011
- Prospects for Simultaneous Global Development: 1 (2)
January 3, 2011
- M3 to Expand Its e-Detailing Services in Oncology
January 3, 2011
- Seikagaku to File NDA for SI-6603 in Mid 2011
January 3, 2011
- PSJ to Raise Public Awareness of Drugs
January 3, 2011
- Ono Obtains Positive PIIb Results for Carfilzomib
January 3, 2011
- Otsuka HD Places Top Priority on Development of OPC-34712
January 3, 2011
- Sanofi-aventis Extends Tender Offer for Genzyme Shares
December 20, 2010
- Novel Anticoagulants Gaining Popularity: Dr Yamashita
December 20, 2010
- Fixed-Dose Combination Eye Drops Improve Compliance: Dr Araie
December 20, 2010
- Mediscience to Acquire CRO Business from Tokyo Clinical CRO
December 20, 2010
- Industry Support Essential for iPS Cell Drug Discovery: Prof. Yamanaka
December 20, 2010
- NCGM Compiles Manual for Selection of Antidiabetic Drugs for GPs
December 20, 2010
- MTPC Takes Confidence-Building Measures
December 20, 2010
- JPMA Willing to Support iPS Drug Discovery: President Hasegawa
December 20, 2010
- Eisai, SymBio: Anticancer Agent TREAKISYM
December 20, 2010
- Sanofi Pasteur to Enhance Its Presence in Japan: General Manager Perraudin
December 20, 2010
- NPhA Casts Doubt on Drug Wholesalers' Rx Pharmacy Business
December 20, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…